Apellis Pharmaceuticals Inc (APLS)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$40.40
Buy
$40.45
$0.02 (+0.05%)
Prices updated at 03 Apr 2026, 00:26 EDT
| Prices minimum 15 mins delay
Prices in USD
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Gerald L. Chan, Sc.D.
CEO
Dr. Cedric Francois, M.D.
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
733
Head office
100 Fifth Avenue
Waltham
United States
02451
Key personnel
Owner name | Salary |
|---|---|
Dr. G. Mikael Dolsten, M.D.,PhD Independent Director | - |
Mr. Craig A. Wheeler Independent Director | - |
Mr. Alec Machiels Independent Director | 0.09m |
Dr. Gerald L. Chan, Sc.D. Chairman of the Board | 0.10m |
Ms. Stephanie Monaghan O’Brien Independent Director | 0.09m |
Mr. Timothy E. Sullivan Chief Financial Officer and Treasurer | 0.53m |
Dr. Cedric Francois, M.D. Director, Chief Executive Officer and President | 0.79m |
Mr. A. Sinclair Dunlop Independent Director | 0.08m |
Mr. Paul Fonteyne, M.S. Independent Director | 0.09m |
Mr. James George Chopas Vice President, Corporate Controller, Treasurer and Chief Accounting Officer | - |
Ms. Keli Walbert Independent Director | - |
Mr. David Acheson Executive Vice President, Commercial | - |
Mr. Pascal Deschatelets, PhD Chief Scientific Officer | - |
Mr. David Watson General Counsel and Secretary | 0.51m |
Ms. Nur Nicholson Chief Technical Operations Officer | - |
Mr. Mark Jeffrey DeLong Chief Business and Strategy Officer | - |
Dr. Caroline Baumal, M.D. Chief Medical Officer | 0.61m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Wellington Management Company LLP | 12,721,352 |
| venBio Select Advisor LLC | 12,222,222 |
| Vanguard Group Inc | 10,674,865 |
| BlackRock Fund Advisors | 9,850,003 |
| Morgan Stanley - Brokerage Accounts | 9,643,248 |
Director dealings
Date | Action |
|---|---|
| 16 Dec 2025 | - |
| 17 Nov 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
| 21 Oct 2025 | - |
| 16 Oct 2025 | - |
| 30 Sep 2025 | - |
| 30 Sep 2025 | - |
| 19 Sep 2025 | - |
| 19 Sep 2025 | - |
| 16 Sep 2025 | - |
| 15 Sep 2025 | - |
| 10 Sep 2025 | - |
| 08 Sep 2025 | - |
| 08 Sep 2025 | - |
| 08 Sep 2025 | - |
| 08 Sep 2025 | - |
| 02 Sep 2025 | - |
| 02 Sep 2025 | - |
| 02 Sep 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
